In SURMOUNT 4, all participants received the maximum tolerated dose of tirzepatide for 36 weeks and were then randomized 1:1 to continue tirzepatide or receive placebo until 88 weeks
The combination rationale, ratios and a pre-combined research preparation are covered in the dedicated BPC-157 + TB-500 stack research guide
The pharmacokinetic groundwork that is also missing Even before an efficacy trial, injectable GHK-Cu lacks the basic human pharmacokinetic characterization that any injectable drug candidate would require: measured plasma half-life of the intact complex, the fraction of administered copper that binds to plasma proteins versus remains peptide-bound, tissue distribution, and how much functional complex if any actually reaches the dermis
Certain peptides are commonly discussed for tissue repair, inflammation control, and recovery support, including BPC-157, Thymosin Beta-4, and LL-37